Phase II Study With Lead-in Safety Cohort of Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
Phase of Trial: Phase II
Latest Information Update: 05 Jul 2017
Price : $35 *
At a glance
- Drugs Cabazitaxel (Primary) ; Lapatinib (Primary)
- Indications Advanced breast cancer; Brain metastases
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 02 May 2017 Status changed from active, no longer recruiting to discontinued.
- 03 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Apr 2017.